Akebia Therapeutics Inc. AKBA

NAS: AKBA | ISIN: US00972D1054   20/12/2024
1,830 USD (+2,23%)
(+2,23%)   20/12/2024

Akebia Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 26, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its executives will participate in two investor conferences in September: Wells Fargo Healthcare Conference on September 4-6, 2024 in Boston and H.C. Wainwright 26th Annual Global Investment Conference on September 9-11, 2024 in New York.  

Wells Fargo Healthcare Conference
John Butler, Chief Executive Officer, will present on Friday, September 6 at 9:30 a.m. EST.

H.C. Wainwright Global Investment Conference
Mr. Butler will participate in a fireside chat on Monday, September 9 at 10:30 a.m. EST.

A webcast of each presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com following the conferences. A replay of the webcast will also be available for approximately 90 days following the conference through the Investors section of Akebia's website at https://ir.akebia.com.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-upcoming-investor-conferences-302229594.html

SOURCE Akebia Therapeutics

Mijn selecties